Since KRAS/NRAS/BRAF genes are involved in the MAPK pathway, the use of MAPK inhibitors in combination with immunomodulatory drugs in MM patients with mutations in these genes is being discussed [9]. This evidence concerns the gene NRAS and Miyoshi myopathy.